EIGR - Eiger BioPharmaceuticals Inc
Close
1.725
-0.175 -10.145%
Share volume: 137,824
Last Updated: Wed 10 Apr 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.90
-0.18
-9.21%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-05 | 2022-08-04 | 2022-11-03 | 2023-03-17 | 2023-05-11 | 2023-08-14 | 2023-11-09 | |
| Assets | ||||||||
| Total Assets | 153.329 M | 163.691 M | 143.744 M | 120.139 M | 99.228 M | 72.358 M | 55.654 M | |
| Current Assets | 147.356 M | 157.703 M | 142.289 M | 117.535 M | 96.911 M | 70.484 M | 54.624 M | |
| Inventories | 1.910 M | 2.876 M | 2.817 M | 2.853 M | 5.338 M | 1.098 M | 1.105 M | |
| Other Current Assets | 10.442 M | 11.997 M | 15.970 M | 13.985 M | 12.410 M | 12.062 M | 12.777 M | |
| Short Term Investments | 10.442 M | 11.997 M | 15.970 M | 13.985 M | 12.410 M | 12.062 M | 12.777 M | |
| Total Receivables | 2.287 M | 1.038 M | 2.458 M | 1.749 M | 3.891 M | 3.715 M | 1.321 M | |
| Current Cash | 132.717 M | 141.792 M | 121.044 M | 98.948 M | 75.272 M | 53.609 M | 39.421 M | |
| Total Non-current Assets | 5.973 M | 5.988 M | 1.455 M | 2.604 M | 2.317 M | 1.874 M | 1.030 M | |
| Property Plant Equipment | 545.000 K | 525.000 K | 511.000 K | 696.000 K | 804.000 K | 755.000 K | 677.000 K | |
| Other Assets | 5.428 M | 5.463 M | 944.000 K | 1.908 M | 1.513 M | 1.119 M | 353.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 153.329 M | 163.691 M | 143.744 M | 120.139 M | 99.228 M | 72.358 M | 55.654 M | |
| Total liabilities | 56.062 M | 60.766 M | 65.436 M | 64.829 M | 63.989 M | 57.063 M | 57.258 M | |
| Total current liabilities | 36.612 M | 21.847 M | 26.119 M | 25.121 M | 23.999 M | 16.713 M | 16.524 M | |
| Accounts Payable | 9.218 M | 9.945 M | 10.497 M | 8.975 M | 11.858 M | 4.946 M | 4.858 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 13.139 M | 436.000 K | 277.000 K | 491.000 K | 435.000 K | 321.000 K | 205.000 K | |
| Long term debt | 19.450 M | 38.919 M | 39.317 M | 39.708 M | 39.990 M | 40.350 M | 40.734 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 97.267 M | 102.925 M | 78.308 M | 55.310 M | 35.239 M | 15.295 M | -1.604 M | |
| Common stock | 35.253 M | 43.060 M | 44.011 M | 44.189 M | 44.146 M | 44.296 M | 44.320 M | |
| Retained earnings | -363.060 M | -384.944 M | -412.055 M | -437.193 M | -459.977 M | -480.672 M | -498.702 M |